Erleada (apalutamide) vs Akeega (niraparib and abiraterone acetate)

Erleada (apalutamide) is an androgen receptor inhibitor indicated primarily for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC), working by blocking the effect of androgens, which can slow the growth of prostate cancer cells. Akeega, which combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, is used for metastatic castration-resistant prostate cancer (mCRPC) and targets cancer cells by interfering with DNA repair mechanisms and androgen biosynthesis. When deciding between Erleada and Akeega, it is crucial to consider the stage and progression of prostate cancer, as well as the specific mechanism of action of each medication, with Erleada being more suitable for non-metastatic cases and Akeega tailored for metastatic cases, always under the guidance of an oncologist.

Difference between Erleada and Akeega

Metric	Erleada (apalutamide)	Akeega (niraparib and abiraterone acetate)
Generic name	Apalutamide	Niraparib and Abiraterone Acetate
Indications	Non-metastatic castration-resistant prostate cancer (nmCRPC), metastatic castration-sensitive prostate cancer (mCSPC)	Not specified; combination not typically used together in standard treatment protocols
Mechanism of action	Androgen receptor inhibitor	Niraparib: PARP inhibitor; Abiraterone Acetate: CYP17 inhibitor
Brand names	Erleada	Niraparib: Zejula; Abiraterone Acetate: Zytiga
Administrative route	Oral	Oral
Side effects	Fatigue, hypertension, rash, diarrhea, nausea, weight loss, arthralgia, falls, hot flush, decreased appetite, fractures	Niraparib: Thrombocytopenia, anemia, neutropenia, nausea, constipation, vomiting, abdominal pain, fatigue; Abiraterone Acetate: Hypertension, hypokalemia, edema, elevated liver enzymes, urinary tract infection
Contraindications	Pregnancy, severe hepatic impairment	Niraparib: Myelodysplastic syndrome/acute myeloid leukemia, severe hepatic impairment; Abiraterone Acetate: Severe hepatic impairment, pregnancy
Drug class	Antiandrogen	Niraparib: PARP inhibitor; Abiraterone Acetate: CYP17 inhibitor
Manufacturer	Janssen Biotech, Inc.	Niraparib: GlaxoSmithKline; Abiraterone Acetate: Janssen Biotech, Inc.

Efficacy

Erleada (Apalutamide) for Prostate Cancer

Erleada (apalutamide) is a medication that has been approved for the treatment of prostate cancer in specific contexts. It is particularly efficacious in treating non-metastatic castration-resistant prostate cancer (nmCRPC). Clinical trials have demonstrated that apalutamide significantly extends metastasis-free survival in patients with nmCRPC. This is an important consideration, as delaying the spread of cancer can improve quality of life and potentially extend survival. Apalutamide works by inhibiting the action of androgens, such as testosterone, which can fuel the growth of prostate cancer cells.

Akeega (Niraparib and Abiraterone Acetate) for Prostate Cancer

Akeega combines two active substances, niraparib and abiraterone acetate, and is used in the treatment of prostate cancer. Abiraterone acetate is a well-established medication that targets androgen production, which is crucial for the growth of prostate cancer cells. When used in combination with prednisone or prednisolone, abiraterone has been shown to improve survival in men with metastatic castration-resistant prostate cancer (mCRPC). Niraparib, a PARP inhibitor, has shown promise in enhancing the efficacy of treatments like abiraterone by further interfering with the DNA repair mechanisms that cancer cells rely on to survive.

The efficacy of Akeega specifically in prostate cancer is an area of ongoing research, and it is important to note that the combination of niraparib and abiraterone acetate in Akeega is designed to leverage the complementary mechanisms of action of both drugs. However, the use of niraparib in combination with abiraterone acetate is an example of an off-label use, and clinical trials are necessary to fully understand the benefits and risks of this combination in the context of prostate cancer treatment.

In conclusion, both Erleada and Akeega represent important advancements in the treatment of prostate cancer. Erleada has established efficacy in improving metastasis-free survival in patients with nmCRPC, while Akeega, through its combination of niraparib and abiraterone acetate, is being investigated for its potential to enhance outcomes in patients with mCRPC. Patients and healthcare providers should consider the most current research and clinical guidelines when evaluating these treatments for prostate cancer.

Regulatory Agency Approvals

Erleada

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Therapeutic Goods Administration (TGA), Australia

Akeega

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA

Access Erleada or Akeega today

If Erleada or Akeega are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Erleada

Buy Akeega

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: